cas 34381-71-0|| where to buy [(2S)-1-methylpyrrolidin-2-yl]methanol

Nom du produit:[(2S)-1-methylpyrrolidin-2-yl]methanol

IUPAC Name:[(2S)-1-methylpyrrolidin-2-yl]methanol

Unité d'emballage	Stock disponible	Prix($)
CM328420-100g	in stock	ǭĜŽ
CM328420-500g	in stock	řƏǎ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 34381-71-0 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:34381-71-0; Formule moléculaire:C6H13NO; Point de fusion:-; Code SMILES:OC[C@H]1N(C)CCC1; Densité:

: Numéro de catalogue:CM328420; Poids moléculaire:115.18; Point d'ébullition:; N° Mdl:MFCD00011727; Stockage:

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Adagrasib; Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.